S. Safabakhsh

Oct 8, 2024 | onlinecjc.ca | S. Safabakhsh |Y. Luo |A. Palumbo |Q. N. Chan |C. Fiset |C. Shen | +3 more

Numerous reports have described important sex-based differences in the clinical presentation and outcome of patients with heart disease. Trials are ongoing to further understand these observations and to evaluate various approaches towards their clinical management. However, an understanding of the basic mechanisms that result in the sexually dimorphic expression of cardiovascular disease remain lacking.

Oct 8, 2024 | onlinecjc.ca | S. Safabakhsh |R. Pancaroglu |D. S. Dissanayake |J. Parker |S. Barichello |P. Panwar | +4 more

Atrial fibrillation (AF) is the most common sustained arrhythmia. Currently, there are no biomarkers available for monitoring AF progression or for serving as targets for disease-modifying therapies. Research in this area is increasingly pointing to a role for post-translational phosphorylation of cardiac ryanodine receptor 2 (RyR2) as a promising avenue for biomarker discovery. Most studies of RyR2 phosphorylation in AF have focused on single phosphorylation sites using antibody-based assays.